Formulation variation and in vitro-in vivo correlation for a rapidly swellable three-layered tablet of tamsulosin HCl

Chemical and Pharmaceutical Bulletin

Volumn 59, Issue 5, 2011, Pages 529-535

  Park, Jun Sang ^a,b   Shim, Ji Yeon ^a   Park, Jung Soo ^a   Lee, Myung Jae ^a   Kang, Jong Min ^a   Lee, Sung Hoon ^a   Kwon, Min Chang ^a   Choi, Young Wook ^b   Jeong, Seong Hoon ^c  

^a GL PharmTech Corporation   (South Korea)

^b Chung Ang University   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

Beagle dog; Controlled release; In vitro in vivo correlation; Swelling; Tamsulosin; Three layered tablet

Indexed keywords

TAMSULOSIN; TAMSULOSIN OCAS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG FORMULATION; DRUG SOLUBILITY; EXPERIMENTAL DOG; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; WATER TRANSPORT;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOGS; DRUG ADMINISTRATION SCHEDULE; MOLECULAR WEIGHT; SOLUBILITY; SULFONAMIDES; TABLETS; TIME FACTORS;

EID: 79955626580     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.59.529     Document Type: Article

References (23)

1. Park Jun S., Shim J. Y., Park Jung S., Choi Y. W., Jeong S. H., Drug Dev. Ind. Pharm., (2011) (DOI: 10.3109/03639045.2010.535211).
2. Abrams P., Schulman C. C., Vaage S., Br. J. Urol., 76, 325-336 (1995).
3. Michel M. C., Korstanje C., Krauwinkel W., Kuipers M., Eur. Urol. Suppl., 4, 15-24 (2005).
4. Witte D. G., Brune M. E., Katwala S. P., Milicic I., Stolarik D., Hui Y. H., Marsh K. C., Kerwin J. F. Jr., Meyer M. D., Hancock A. A., J. Pharmacol. Exp. Ther., 300, 495-504 (2002).
5. Michel M. C., Korstanje C., Krauwinkel W., Eur. Urol. Suppl., 4, 9-14 (2005).
6. Chapple C. R., Eur. Urol. Suppl., 4, 1-4 (2005).
7. Stevens H. N. E., Speakman M., Curr. Med. Res. Opin., 22, 2323-2328 (2006).
8. Sako K., Mizumoto T., Kajiyama A., Ohmura T., Int. J. Pharm., 137, 225-232 (1996).
9. Sako K., Nakashima H., Sawada T., Fukui M., Pharm. Res., 13, 594-598 (1996).
10. Kim C. J., J. Pharm. Sci., 84, 303-306 (1995).
11. Shah V. P., Tsong Y., Sathe P., Liu J. P., Pharm. Res., 15, 889-896 (1998).
12. Costa P., Lobo J. M. S., Eur. J. Pharm. Biopharm., 13, 123-133 (2001).
13. Wagner J. O., Biopharm. Drug Dispos., 4, 359-373 (1983).
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, "Guidance for Industry," September, 1997.
15. Streubel A., Siepmann J., Peppas N. A., Bodmeier R., J. Controlled Release, 69, 455-468 (2000).
16. Maggi L., Bruni R., Conte U., Int. J. Pharm., 195, 229-238 (2000).
17. Yang L., Fassihi R., Int. J. Pharm., 155, 219-229 (1997).
18. Katori N., Aoyagi N., Terao T., Pharm. Res., 12, 237-243 (1995).
19. Shameem M., Katori N., Aoyagi N., Kojima S., Pharm. Res., 12, 1049-1054 (1995).
20. Sawada T., Sako K., Fukui M., Yokohama S., Hayashi M., Int. J. Pharm., 265, 55-63 (2003).
21. Ranga Rao K. V., Padmalatha Devi K., Buri P., J. Controlled Release, 12, 133-141 (1990).
22. Mitchel K., Ford J. L., Armstrong D. J., Elliott P. N., Hogan J. E., Rostron C., Int. J. Pharm., 100, 165-173 (100).
23. Matsushima H., Kamimura H., Soeishi Y., Watanabe T., Higuchi S., Tsunoo M., Drug Metab. Dispos., 26, 240-245 (1998).